<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04842422</url>
  </required_header>
  <id_info>
    <org_study_id>12020</org_study_id>
    <nct_id>NCT04842422</nct_id>
  </id_info>
  <brief_title>Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream</brief_title>
  <official_title>Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Earliest Stage Treatment of Actinic Keratosis with Imiquimod 3.75% Cream:&#xD;
&#xD;
      The study is to demonstrate that Aktinic Keratosis are present before they are clinically&#xD;
      visible, i.e. in a subclinical stage. Since on the basis of the research situation, also&#xD;
      subclinical AK can proliferate into the dermis, it is possible that with the application of&#xD;
      Imiquimod on chronically light-exposed skin, undetected squamous cell carcinoma can be&#xD;
      recognized and treated at the same time.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>immunomodulatory-induced inflammatory reaction</measure>
    <time_frame>two weeks</time_frame>
    <description>Percentage of subjects in whom an immunomodulatory-induced inflammatory reaction occurs on chronically light-exposed uv-damaged facial skin after two weeks.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Actinic Keratoses</condition>
  <arm_group>
    <arm_group_label>Earliest Stage Treatment of Aktinic Keratosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod 3.75% Cream</intervention_name>
    <description>Imiquimod 3.75% Cream</description>
    <arm_group_label>Earliest Stage Treatment of Aktinic Keratosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion&#xD;
&#xD;
          -  Male and female supposed-healthy volunteer outpatients, age: &gt; 50 years.&#xD;
&#xD;
          -  Diagnosis: patients with chronically UV-exposed photodamaged facial skin.&#xD;
&#xD;
          -  Consent by signing the ICF (Informed Consent Form)&#xD;
&#xD;
        Exclusion&#xD;
&#xD;
          -  Current participation in another clinical trial&#xD;
&#xD;
          -  Patients who are using topical glucocorticoids on the face.&#xD;
&#xD;
          -  Known intolerance/hypersensitivity to imiquimod&#xD;
&#xD;
          -  Pregnant/breastfeeding women&#xD;
&#xD;
          -  Systemic disease, immunodeficiency&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Daisy Kopera, Prof.</last_name>
    <email>daisy.kopera@medunigraz.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinik für Dermatologie und Venerologie</name>
      <address>
        <city>Graz</city>
        <zip>8010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daisy Kopera, Prof.</last_name>
    </contact>
    <contact_backup>
      <email>daisy.kopera@medunigraz.at</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 8, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

